What is Sarepta Therapeutics, Inc.'s EV / sales?

Sarepta Therapeutics, Inc. (SRPT) reported EV / sales of 0.9× in Q1 2026.

What is the long-term trend for Sarepta Therapeutics, Inc.'s EV / sales?

Over 4 years (2020 to 2025), Sarepta Therapeutics, Inc.'s EV / sales has grown at a -57.2% compound annual growth rate (CAGR), from 22.5× to 0.8×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Sarepta Therapeutics, Inc. SRPT EV / sales

EV / sales at other companies

PfizerPFE

3.5×+0.3×

Regeneron PharmaceuticalsREGN

5.5×+0.6×

BioMarin PharmaceuticalsBMRN

2.8×-1.6×

PTC TherapeuticsPTCT

6.3×+4.6×

InsmedINSM

43×+4.8×

Capricor TherapeuticsCAPR

29.2×+8.8×

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.82B-63.1%

Enterprise value$1.56B-67.2%

P/S0.8×—

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

enterprise value/total revenue=0.9×

Based on the most recent quarter.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s EV / sales?: Sarepta Therapeutics, Inc. (SRPT) reported EV / sales of 0.9× in Q1 2026.
What is the long-term trend for Sarepta Therapeutics, Inc.'s EV / sales?: Over 4 years (2020 to 2025), Sarepta Therapeutics, Inc.'s EV / sales has grown at a -57.2% compound annual growth rate (CAGR), from 22.5× to 0.8×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.